研究证据生成地点是否会影响其转化为临床实践? 一个协议文件,一个协议文件
Dai Pu1, Debra Mitchell1, Natasha Brusco1,2
1School of Primary and Allied Health Care, Faculty of Medicine, Nursing and Health Sciences, Monash University, Frankston, Australia.
PloS one
|December 13, 2024
概括
了解研究与实践之间的差距对于医疗保健至关重要. 本研究探讨了研究中的直接参与如何影响采用基于证据的干预措施,如预防跌倒的动员报警.
科学领域:
- 医疗实施科学 医疗实施科学
- 改善临床实践的改善
- 医疗服务研究 医疗服务研究
背景情况:
- 研究证据在临床实践中的采用受到系统复杂性和上下文因素的阻碍.
- 卫生专业人员往往优先考虑当地信息,而不是外部学术研究.
- 弥合研究与实践之间的差距需要将证据与内在价值观保持一致.
研究的目的:
- 调查研究参与对采用研究建议的影响.
- 将参与证据生成的病房与不参与的病房之间的证据实施进行比较.
- 评估防摔动员报警的有效性和成本效益.
主要方法:
- 一个混合方法研究,具有准实验设计.
- 在澳大利亚维多利亚州的36个医院病房传播动员报警的研究证据.
- 在三个时间点收集定量和定性数据,以衡量证据的吸收.
主要成果:
- 数据收集和分析正在进行中;结果将表明参与和不参与病房之间的吸收差异.
- 该研究旨在量化直接研究经验对证据实施的影响.
- 调查结果将为减少研究与实践差距的战略提供信息.
结论:
- 直接参与研究可以加强基于证据的实践的实施.
- 了解上下文因素是成功翻译医疗保健研究的关键.
- 这项研究将通过基于证据的干预措施为改善医疗保健提供提供宝贵的见解.
相关概念视频
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Translation
14.5K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
Translation Produces the Building Blocks of Life
Proteins are...
14.5K
Initiation of Translation
31.0K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
31.0K
Improving Translational Accuracy
9.0K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
9.0K


